title: Complement factors C3a and C5a have distinct hemodynamic effects in the rat.
abstract: In the rat, C5a infusion mediates well-defined effects including hypotension and neutropenia. Conversely, the comparative effect of C3a in the rat is not yet defined. In the current study, we have investigated C3a receptor (C3aR) activation in the rat, using recombinant human C3a, the C3aR agonist WWGKKYRASKLGLAR, which is a C-terminal analogue of C3a, and a nonpeptide C3aR antagonist SB-290157, as pharmacological tools. In vitro, C3a and WWGKKYRASKLGLAR selectively bound to C3aRs and induced degranulation of C3aR-transfected RBL-2H3 cells. C3a or WWGKKYRASKLGLAR-induced degranulation was dose-dependently antagonized in a surmountable fashion by the nonpeptide C3aR antagonist. Intravenous infusion of C3a and WWGKKYRASKLGLAR to rats induced a rapid, transient and concentration-dependent hypertensive response, which was mediated by C3aR-induced prostanoid release. C3a and WWGKKYRASKLGLAR caused a small drop in circulating neutrophils, but a rise in circulating neutrophils was evident after 90-120 min. In contrast to C3a, C5a infusion resulted in hypotension, and rapid and transient neutropenia. These results demonstrate that C3a and C5a mediate distinct effects on blood pressure and circulating polymorphonuclear leukocytes in the rat.
authors.affiliation: School of Biomedical Sciences, The University of Queensland, Brisbane 4072, Australia.
authors.forename: Lavinia M
authors.initials: LM
authors.lastname: Proctor
authors.forename: Tyson A
authors.initials: TA
authors.lastname: Moore
authors.forename: Peter N
authors.initials: PN
authors.lastname: Monk
authors.forename: Sam D
authors.initials: SD
authors.lastname: Sanderson
authors.forename: Stephen M
authors.initials: SM
authors.lastname: Taylor
authors.forename: Trent M
authors.initials: TM
authors.lastname: Woodruff
mesh_terms: D000818:Animals; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D001559:Benzhydryl Compounds / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D015550:Cell Degranulation; D002460:Cell Line; D015926:Complement C3a / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D015936:Complement C5a / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D005260:Female; D006801:Humans; D009503:Neutropenia / Q000276:immunology / Q000378:metabolism; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D043562:Receptors, G-Protein-Coupled / Q000819:agonists / Q000037:antagonists & inhibitors; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D001559:Benzhydryl Compounds; D010455:Peptides; D043562:Receptors, G-Protein-Coupled; D011994:Recombinant Proteins; C431907:SB 290157; C542791:WWGKKYRASKLGCAR peptide; C532341:anaphylatoxin receptor C3a, rat; D015926:Complement C3a; D015936:Complement C5a; D001120:Arginine